{
  "slug": "peptide-stacks-recovery",
  "round": 2,
  "group": 12,
  "date": "2026-10-14",
  "authoring_model": "Sol 6.1",
  "adversarial_reviewer": "Claude Opus 5.5 (Anthropic)",
  "canonical_path": "hsef_v53_traffic_ranks_06_10_2026-10-13/peptide-stacks-recovery/peptide-stacks-recovery.review.md",
  "propagated_to": [
    "hsef_v53_topical_all_22_2026-10-13/cycles/hsef_v53_traffic_ranks_06_10_2026-10-13_share/peptide-stacks-recovery/ (review.md, scorecard.json, ADVERSARIAL_REVIEW.md, adversarial-findings.json, sol61-original/)",
    "hsef_v53_traffic_ranks_06_10_2026-10-13_share/peptide-stacks-recovery/ (review.md, scorecard.json, ADVERSARIAL_REVIEW.md, adversarial-findings.json, sol61-original/)"
  ],
  "propagation_verified": "Lead propagation rule (2026-10-14) applied: every artifact that was byte-identical before the edit was propagated, not only the review.md named in the inventory. Pre-edit identity of both edited artifacts is evidenced by each copy's own SHA256.txt, which records the pre-edit canonical hashes 2bdd6f12... (review) and e5e61250... (score card). A full walk of the three folders after the edit confirms all 17 common files byte-identical, with no file present in a share copy and absent from the canonical. Post-edit hashes: review 9d7df60d1ce1631d7765aab2c2ea2f52678f75db30804286a476ad9e4a17d7a4, score card f0075ac2de85c3f7f52bd353d57062caf83ac1c06cc56c0baaec5873cac895de. sol61-original/ backups of both files now exist in each of the three copies. SHA256.txt was left as a pre-review snapshot and is equally stale in all three, so copy identity holds.",
  "divergent_copies_not_touched": [],
  "level_before": "Γ",
  "level_after": "Γ",
  "confidence_before": "Moderate",
  "confidence_after": "Moderate",
  "role_before": "epiphenomenon",
  "role_after": "epiphenomenon",
  "pmids_checked": 56,
  "pmids_failed": 0,
  "retractions_or_eoc_found": 0,
  "claims_spot_checked": 13,
  "validator": {
    "before": "PASS — 0 fail, 0 warn, 30 pass",
    "after": "PASS — 0 fail, 0 warn, 30 pass (identical)"
  },
  "findings": [
    {
      "id": "AR-1",
      "severity": "Minor",
      "type": "confidence_justified_by_access_depth",
      "location": [
        "scorecard final_score.confidence_rationale"
      ],
      "original": "56 primary reports with 3 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.",
      "corrected": "Rationale restated on evidence-density and reproducibility grounds (two blinded CJC-1295 reports, human ipamorelin pharmacodynamics, several controlled GH or secretagogue functional trials, persisting heterogeneity across molecules, routes, exposures and endpoints, exact combination untested), explicitly excluding the reviewer's access depth.",
      "evidence": "Lead two-step test (2026-10-14). Step 1: access depth struck as a determinant. Step 2: band re-derived from what remains and retained at Moderate, since the review documents substantive evidence-quality reservations. The framework states that confidence reflects evidence density and reproducibility, not reviewer access. Moderate is retained because the Moderate text is met on its own terms and High is not: nothing replicates the exact combination at all.",
      "level_impact": "none; band unchanged at Moderate"
    },
    {
      "id": "AR-2",
      "severity": "Minor",
      "type": "missing_required_artifact",
      "location": [
        "Final score block, Divergence line",
        "scorecard extended_scoring_MSD.divergence.justification"
      ],
      "original": "Contested. No manufactured field consensus or arithmetic gap.",
      "corrected": "Same value, now naming the split: clinic and vendor framing of the exact stack as an established recovery aid against an examined literature with no exact-combination functional test and several same-axis functional nulls (PMID18981485,25331030,1550219,7864103).",
      "evidence": "Divergence is computed, not felt; Contested requires showing a genuine split. Both prose and score card previously asserted only the absence of an arithmetic gap."
    },
    {
      "id": "AR-3",
      "severity": "Minor",
      "type": "rendering_defect_empty_doi",
      "location": [
        "References 8 (PMID 19068595) and 42 (PMID 28976342)"
      ],
      "original": "DOI: .",
      "corrected": "DOI: not available.",
      "evidence": "Builder emits the field even when PubMed carries no DOI. Verified that PubMed supplies no DOI for either record, so only the empty field needed repair."
    },
    {
      "id": "AR-4",
      "severity": "Editorial",
      "type": "rendering_defect_fused_tokens",
      "location": [
        "Deciding experiment",
        "AT A GLANCE",
        "rank-3 competing model",
        "inventory items [52] [55] [56]",
        "cap audit",
        "Consensus reconciliation",
        "boundary experiment",
        "momentum artifact",
        "matching scorecard fields"
      ],
      "original": "over4-24 (x3), and7864103, ROMANA26906526, Rubric06, and26-week (x2), of25.3 and32.6, blinded96-athlete, Universal cap4, examined2026, the2026, thymosinbeta4 (x4), a3.9percent, GH:39 (x2), VO 2 max (x4)",
      "corrected": "spaces restored (22 tokens across the review and the score card)",
      "evidence": "The 'randomize3808' rendering class, pervasive in this package. Molecule names, dose strings, DOIs, PMIDs, trial registry numbers and body-receipt paragraph handles were left untouched."
    }
  ],
  "rejected_findings": [
    {
      "id": "RJ-1",
      "claim": "The headline should be Delta (single-agent GH-axis activation plus positive comparator trials) or Beta (mechanism is mere co-occurrence).",
      "resolution": "Rejected both. Primary-subclaim is pre-registered and applied as written: SC2 carries the registered clinical proposition and its Gamma sets the headline, with SC1, SC3 and SC4 reported without gating, and all three alternatives reported (weakest-link Alpha, primary-subclaim Gamma, scope-matched Gamma). Delta fails because no positive controlled functional or healing endpoint for the exact combination in the registered population was verified. Beta fails because human component pharmacodynamics and preclinical receptor-blockade and repair interventions supply more than co-occurrence."
    },
    {
      "id": "RJ-2",
      "claim": "'Best-supported rival' prints the nominal model (the renderer bug reported elsewhere this round).",
      "resolution": "Rejected; checked and absent. models_evaluated[0] is is_nominal false at rank 1, so the printed rival is genuinely the highest-ranked non-nominal model. The nominal sits at rank 4."
    },
    {
      "id": "RJ-3",
      "claim": "The causal role should not be 'epiphenomenon'.",
      "resolution": "Rejected. The derivation procedure reaches epiphenomenon at step 2 (no demonstrated causal dependency in either direction), and the review states explicitly that this is an evidence-state classification rather than a claim of biological inactivity."
    },
    {
      "id": "RJ-4",
      "claim": "Momentum understates or overstates activity.",
      "resolution": "Rejected. 'Mechanistic only' is correct and the artifact names the work. No upgrade is available because no exact-combination clinical programme was identified."
    },
    {
      "id": "RJ-5",
      "claim": "Safety or efficacy claims are overstated or understated (the point of special concern for an unapproved consumer product).",
      "resolution": "Rejected after a dedicated audit; accurate in both directions. The high-dose GH mortality result is correctly reported and bounded to prolonged critical illness, and the review itself refuses to use any unverified CJC-associated death allegation. Harms are not inflated (the rat tendon-bone finding is held to its model and dose; the product-identity report to one sampled product). Benefits are not understated: the 3.9 percent sprint gain in 96 athletes with loss after washout, the hip-replacement walking benefit and the capromorelin tandem-walk and stair-climb results are all retained. The net-benefit subclaim stays at Alpha in both directions."
    },
    {
      "id": "RJ-6",
      "claim": "Numeric claims disagree with the sources.",
      "resolution": "Rejected; verified against PubMed abstracts. Ipamorelin ileus 117 enrolled, medians 25.3 and 32.6 hours at p=0.15; MK-677 65 participants; ROMANA 1 and 2 totalling 979 with co-primary lean body mass and handgrip strength; Blackman factorial 131 (57 women, 74 men) over 26 weeks; GH receptor antagonist in 20 healthy men; the four-arm Achilles study with 32 rats in groups of eight, significant only for TB-500 alone; CJC-1295 identified as a twenty-nine-amino-acid peptide in one unknown marketed product."
    },
    {
      "id": "RJ-7",
      "claim": "Reference years disagree with PubMed.",
      "resolution": "Rejected per convention. References 1, 16, 22, 24 and 45 differ from the PubMed e-pub year by one."
    },
    {
      "id": "RJ-8",
      "claim": "Collective-author defect, 'PMIDnot supplied', false approval boilerplate or a REVIEWER NOTES contradiction present.",
      "resolution": "Rejected; screened and none present. This package is not one of the 9 October revised editions, so the spliced provenance clauses do not arise, and the Consensus reconciliation section is internally consistent with REVIEWER NOTES."
    },
    {
      "id": "RJ-9",
      "claim": "Routing a sports-recovery claim to the metabolism and aging rubric is a scoring error.",
      "resolution": "Rejected. The adaptation is declared, the literal frozen criteria are printed unchanged alongside it, and the adaptation explicitly refuses to convert a null or a different molecule into a positive crossing. This is the framework-sanctioned handling of a missing rubric."
    }
  ],
  "residual_limitations": "Only three originals were read at partial-body depth (tesamorelin, MK-677 and the CJC proteomic subset), so Methods-level figures elsewhere rest on abstracts and status records, as the review states. The same fused-token defects corrected here remain in the sibling case artifacts listed in ADVERSARIAL_REVIEW.md. The review does not state in terms that neither CJC-1295 nor ipamorelin is an approved medicine for any indication; checked and not an error, since no approval is asserted anywhere and the approved comparator (tesamorelin) is confined to its HIV indication, but a reader-facing edition would benefit from saying so plainly.",
  "propagation_strings_for_lead": [
    {
      "file_class": "sibling case artifacts and derived pages",
      "old": "over4–24",
      "new": "over 4–24"
    },
    {
      "file_class": "sibling case artifacts and derived pages",
      "old": "and7864103",
      "new": "and 7864103"
    },
    {
      "file_class": "sibling case artifacts and derived pages",
      "old": "ROMANA26906526",
      "new": "ROMANA PMID26906526"
    },
    {
      "file_class": "sibling case artifacts and derived pages",
      "old": "Rubric06",
      "new": "Rubric 06"
    },
    {
      "file_class": "sibling case artifacts and derived pages",
      "old": "and26-week",
      "new": "and 26-week"
    },
    {
      "file_class": "sibling case artifacts and derived pages",
      "old": "of25.3 and32.6",
      "new": "of 25.3 and 32.6"
    },
    {
      "file_class": "sibling case artifacts and derived pages",
      "old": "blinded96-athlete",
      "new": "blinded 96-athlete"
    },
    {
      "file_class": "sibling case artifacts and derived pages",
      "old": "Universal cap4",
      "new": "Universal cap 4"
    },
    {
      "file_class": "sibling case artifacts and derived pages",
      "old": "examined2026",
      "new": "examined 2026"
    },
    {
      "file_class": "sibling case artifacts and derived pages",
      "old": "the2026",
      "new": "the 2026"
    },
    {
      "file_class": "sibling case artifacts and derived pages",
      "old": "thymosinbeta4",
      "new": "thymosin beta4"
    },
    {
      "file_class": "sibling case artifacts and derived pages",
      "old": "a3.9percent",
      "new": "a 3.9 percent"
    },
    {
      "file_class": "sibling case artifacts and derived pages",
      "old": "GH:39",
      "new": "GH: 39"
    },
    {
      "file_class": "sibling case artifacts and derived pages",
      "old": "VO 2 max",
      "new": "VO2 max"
    },
    {
      "file_class": "sibling case artifacts and derived pages",
      "old": "DOI: . Access",
      "new": "DOI: not available. Access"
    }
  ],
  "approval": "Approved as revised. — Claude Opus 5.5 (Anthropic), 2026-10-14."
}